

ADVISORY BOARD

Scientific Advisory Board:

Kathryn J. Wood: Dr. Wood is an internationally renowned transplant immunologist at the University of Oxford, UK. She has served as a leader in the field of transplantation for over thirty years. She has held many executive positions including that of President of the Transplantation Society. She is well published in many high level journals and is leading clinical trials on therapeutics developed in her lab.

Robert Merion: Dr. Merion is a Professor of Surgery in the Section of Transplantation at the University of Michigan. Dr. Merion served for ten years as the Chief of the Division and as Director of the University of Michigan Kidney and Pancreas Transplant Program before assuming the responsibility of Clinical Transplant Director for the federally funded Scientific Registry of Transplant Recipients (SRTR). Dr. Merion is recognized nationally and internationally as a leader in medical informatics, particularly in the field of transplantation, where in addition to his role with the SRTR, he serves in several national informatics leadership positions with the American Society of Transplant Surgeons and the American College of Surgeons. He also currently serves as the President of Arbor Research Collaborative for Health.

Marie-Christine Daniel-Onuta: Dr. Onuta is an associate professor at The University of Maryland Baltimore County. She has a long publication record and extensive research focus on drug delivery systems for cancer therapeutics. She is a highly experienced bioengineer with expertise in nanovectors, gold nanoparticle, and dendrons for example. Currently she applies the strategies to breast, prostate and pancreatic cancer.

Prabhakar Baliga: Dr. Baliga holds the Fitts-Raja Endowed Chair in Transplant Surgery and currently serves as the Chief of the Division of Transplant Surgery at MUSC. He has held many national leadership positions in transplantation and has been a well-respected member of the transplantation community for over twenty years.

Stephen Tomlinson: Dr. Tomlinson is a Professor and the current Vice Chair for Research & Faculty Development Microbiology & Immunology at MUSC. His research focuses on the biology of the complement system. A major focus of his research is the role of complement in ischemia reperfusion injury, transplantation and the modulation of adaptive immune responses. He holds multiple patents, mostly related to design, characterization and construction of novel targeted complement therapeutics and has been intimately involved in the start-up of biotechnology companies.

Alison Smith: Dr. Smith is an Associate Professor in the Department of Comparative Medicine at MUSC. She is the lead veterinarian at the Medical University of South Carolina and has extensive experience in the set-up, design and maintenance of large animal models for research purposes. Dr. Smith's particular interest is in swine models which she has successfully set up at MUSC.

Executive Advisory Board:

Thomas Finnegan: Mr. Finnegan serves as the director of MUSC's Center for Innovation and Entrepreneurship. Prior to that he was Vice President of Finance and

Corporate Development at Introgen Therapeutics, a publicly traded biotech company (NASDAQ: INGN) based in Austin, Texas and portfolio company of Texas Biomedical Partners LLP. His primary responsibilities were to head the finance and business development functions. After taking Introgen public, he raised over \$120 million of public and private capital for the Company. Additional responsibilities included M&A transactions, partner negotiations and strategic alliances, preparation of 10K's, Q's and annual reports, cash management, shareholder functions (IR) and overseeing Public Relations. As head of new business development, he evaluated a lot of business plans and advised several small biotech companies.

Anthony Powell: Mr. Powell is the founder and managing director of KCG, he delivers strategic counsel to businesses and nonprofits across many sectors. He specializes in strategy development, organizational planning, and business process optimization strategies. Prior to KCG, Powell served as the Vice President of Professional Services and Enterprise Sales for Blackbaud (BLKB), a \$300 million technology-solutions company that exclusively serves the global nonprofit market. As an officer of the company, he provided strategic direction and overall P&L management for this 300-person, \$97 million division. During Powell's eight-year tenure at Blackbaud, divisional revenue grew at an annual rate greater than 40% and divisional gross margins consistently exceeded 60%. Prior to his work with Blackbaud, Powell spent 10 years in the nonprofit sector, managing development operations and fundraising campaigns. His nonprofit employment culminated with his leadership role at the Smithsonian Institution in Washington, D.C.

Gautum Ghatnekar, DVM, PhD: Dr. Ghatnekar is the President & CEO of FirstString Research, Inc., a clinical-stage biotechnology company located in Charleston, South Carolina. Dr. Ghatnekar formed the Company in 2005 to license, develop, and commercialize the discovery of a novel connexin-based peptide technology. He served as the Company's Chief Scientific Officer prior to becoming the CEO. He also serves as Board Chairman of Regranion, LLC. Dr. Ghatnekar's experience and expertise in preparing regulatory documentation, developing both GLP preclinical studies and clinical trial protocols; and working knowledge of both the device (CDRH) and drug (CDER) regulatory routes and requirements has led FirstString Research to successfully navigate the FDA and obtain IND approvals.

Legal Counsel:

Wyrick Robbins Yates & Ponton LLP: Wyrick Robbins is an entrepreneurial law firm with a focus on growth-oriented businesses. The firm handles financial and corporate transactions and commercial litigation as well as other legal needs of dynamic companies. Wyrick Robbins attorneys also serve as trusted advisors to founders, investors, directors, and management. ToleRaM Nanotech, LLC was approved to serve as a client of Wyrick Robbins under their Founders Fund.